Clinical Trial Update: Efficacy and Safety of DOV 21,947 in the Treatment of Major Depressive Disorder [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating DOV-21,947 for major depressive disorder reported efficacy and safety data, with the study status listed as terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• DOV 21,947 (DOV-21,947)

Snippet

Sponsor: DOV Pharmaceutical, Inc. | Conditions: Major Depressive Disorder | Phase 2 | Status: TERMINATED